Trial intelligence / Profile preview

Cytisine for nicotine-containing electronic cigarette and tobacco cigarette cessation

2023-504708-27-00Phase 3Authorised

Sponsor
University of Rzeszów
Start
Nov 2023
Modality
Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 3, randomised, double-blind trial in nicotine dependence comparing Cytisine with Placebo (2 arms). Planned start Nov 2023; status: authorised.

02

Drugs

cytisinicline
03

Conditions

nicotine dependence

Beyond the preview

Go deeper on 2023-504708-27-00.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2023-504708-27-00.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call